The Ledger

81 percent: that is how far Doximity’s stock jumped in a single session on a guidance raise built almost entirely on a product that has not booked a dollar of revenue yet. Doximity, the professional network used by most U.S. physicians, reported fiscal first quarter 2027 results after market close August 6, 2026: revenue of 156.6 million dollars, up 7 percent year over year and above the high end of its own guidance, adjusted EBITDA of 74.8 million dollars at a 48 percent margin, and GAAP earnings per share of 0.29 dollars. Shares jumped from a 20.66 dollar close to roughly 37.49 dollars in after hours trading, an 81 percent surge, and were still indicated 70 to 85 percent higher in Friday premarket trading. The company raised full year revenue guidance to a range of 671 to 681 million dollars and adjusted EBITDA guidance to 309 to 329 million dollars, driven by new contracts for Doximity Ask, its clinical AI product, and AI Search, a pharma-facing advertising product management said grew bookings sharply even though the company recognized zero dollars of AI Search revenue in the quarter itself. Confidence: High. The revenue, earnings and guidance figures come directly from Doximity’s own SEC filing and earnings release; the exact share price move is corroborated across multiple market data sources. Sources: Doximity, Inc. Form 8-K, U.S. Securities and Exchange Commission, Doximity Announces Fiscal 2027 First Quarter Financial Results, Business Wire.

76 percent: that is how much GoodRx’s pharma-funded discount channel grew last quarter, now large enough to offset a shrinking legacy business the company was built on. GoodRx reported second quarter 2026 revenue of 200.4 million dollars, down 1.3 percent year over year but above Wall Street’s estimate, with net income of 8.5 million dollars and adjusted EBITDA of 63.7 million dollars at a 31.8 percent margin. Core prescription-transaction revenue, the discount-card business that built the company, fell 26 percent to 106.4 million dollars, while Pharma Direct revenue, GoodRx’s manufacturer-funded discount channel, grew 76 percent to 61.6 million dollars and subscription revenue grew 39 percent to 28.5 million dollars. GoodRx raised full year 2026 guidance to a range of 790 to 805 million dollars in revenue and 240 to 250 million dollars in adjusted EBITDA, ending the first half of the year with 296.1 million dollars in cash. Confidence: High. The figures come directly from GoodRx’s own earnings release. Source: GoodRx Reports Second Quarter 2026 Results, GoodRx Investor Relations.

287.5 million dollars: that is what one cardiac-monitoring device maker is paying to absorb a smaller rival, consolidating two competitors that sell overlapping wearable heart monitors to hospitals. iRhythm Technologies, maker of the Zio patch used for ambulatory cardiac monitoring, agreed to acquire VitalConnect, a maker of multi-parameter vital-sign and mobile cardiac telemetry patches, for 287.5 million dollars, 237.5 million dollars in cash plus 50 million dollars in iRhythm stock. VitalConnect runs at roughly 65 million dollars in annual revenue; the deal was disclosed in an iRhythm SEC filing this week. Confidence: High. The deal terms come directly from iRhythm’s own SEC filing. Source: iRhythm Technologies Form 8-K exhibit, U.S. Securities and Exchange Commission.

4.4 million dollars, plus 100,000 dollars out of a co-founder’s own pocket: that is what California just fined one physician-enablement chain for controlling clinics it was not licensed to control, and it is not the only one. FRONTIER SCAN. California Attorney General Rob Bonta announced a settlement with Carbon Health Technologies and its affiliated professional corporations, which operate more than 80 clinics across 8 states, 54 of them in California, over corporate-practice-of-medicine violations: a 4.4 million dollar penalty on the company plus a first-of-its-kind 100,000 dollar personal penalty on co-founder and former chief executive Eren Bali, alongside findings of deceptive insurance-network advertising and hidden billing practices. The settlement follows a May 7, 2026 settlement with dental chain Aspen Dental, which paid 2 million dollars in civil penalties plus 300,000 dollars in patient restitution and was permanently enjoined from owning practice property or directing clinical staffing and scheduling, now under 36 months of court-ordered compliance monitoring. Both cases rely on Senate Bill 351, effective January 1, 2026, which gave the attorney general direct enforcement authority over management companies that interfere with physician and dentist clinical judgment; a pending appellate case, Art Center Holdings v. WCE CA Art, could extend the theory statewide if California’s Second District Court of Appeal adopts the attorney general’s argument that any contract letting a management company remove a physician-owner is automatically illegal. Elsewhere, similar transaction-oversight bills died this year in New York and Hawaii, while Vermont and Oregon enacted their own restrictions. Confidence: High on the two settlements, which come directly from the California Department of Justice’s own releases. Confidence: Medium on the pending appeal’s status and the New York and Hawaii bill outcomes, sourced to law firm client alerts rather than court or legislative records retrieved directly this run. Sources: Attorney General Bonta Announces First-of-Its-Kind Settlement With Carbon Health, California Department of Justice, Attorney General Bonta Announces Settlement With Aspen Dental, California Department of Justice; per reporting by New York’s Expanded Health Care Transaction Oversight Bill Fails for the Second Consecutive Year, Ropes & Gray.

18 positions: that is how many jobs a small Louisiana hospital just cut, closing an entire specialty clinic it says the numbers no longer support. Lane Regional Medical Center, an independent community hospital in Zachary, Louisiana, confirmed August 6, 2026 that it eliminated 18 positions spanning staff, leadership and physician roles and is closing its Allergy, Asthma and Immunology Clinic. Chief executive Frank Corcoran cited low patient volume alongside “rising operating costs, workforce challenges, and lagging reimbursement rates,” calling the decision “among the most challenging we have faced as an organization.” Confidence: Medium. The cuts and closure are reported directly citing hospital leadership’s own statements, but this run could not independently retrieve a hospital press release or state layoff filing. Source: Lane Regional confirms layoffs amid financial woes, WAFB.

60 percent: that is how much lower a hospital system’s own remote-monitoring vendor says the odds of a 30-day readmission are for the COPD patients using it, which is why the hospital just became one of its investors. UMass Memorial Health, a Massachusetts nonprofit hospital system and an existing multiyear clinical partner, co-led the first close of a 10 million dollar Series B for Wellinks alongside inside investors, disclosed August 4 to 5, 2026. Wellinks sells FDA-cleared remote patient monitoring built around the Spire wearable for chronic obstructive pulmonary disease, and is expanding into congestive heart failure; the companies’ joint “Healthy at Home” program data show more than 60 percent lower odds of 30-day readmission among enrolled COPD patients. Confidence: High. The funding and outcomes figures come directly from Wellinks’ own release. Source: Wellinks Closed $10 Million Series B Funding from UMass Memorial Health and Inside Investors, PR Newswire.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
VitalConnect	iRhythm Technologies	Cardiac and vital-sign monitoring, medtech	$287.5 million ($237.5 million cash plus $50 million stock); target runs at roughly $65 million revenue	iRhythm Technologies Form 8-K exhibit, SEC
Wellinks	UMass Memorial Health and inside investors	Digital health, remote patient monitoring	$10 million Series B, first close; disclosed August 4 to 5, 2026	Wellinks Closed $10 Million Series B Funding, PR Newswire
SkinBit	Boost VC, Cleo Capital, Manna Ventures, Profluent Capital and individual investors including Logan Green	Digital health, AI skin-cancer screening	$6 million pre-seed; disclosed August 5, 2026	SkinBit raises $6M to bring 20-minute full-body skin cancer screening to clinics, TechStartups
Body Vision Medical	Business Asia Consultants and Sprim Global Investments	Medtech, AI intraoperative lung imaging	Undisclosed; closed August 6, 2026	Body Vision Medical Closes New Funding Round, PR Newswire
BroadBranch Advisors	FMG Leading, backed by Copley Equity Partners	Healthcare strategic advisory and market intelligence	Undisclosed	Copley Equity-backed FMG Leading snaps up BroadBranch Advisors, PE Hub
Advanced eClinical Training	Tortuga Growth Partners (Fund I)	Healthcare workforce development, clinical education	Undisclosed	Tortuga Growth Partners Invests in Advanced eClinical Training, PR Newswire